Another MEK inhibitor, selumetinib (AZD6244, AstraZeneca), showed no superior effect in pancreatic cancer patients when compared with conventional cytotoxic chemotherapy [10]. This evidence concerns the gene MAP2K7 and pancreatic neoplasm.